Acelity, a global wound care and regenerative medicine company, announced it has acquired the SNaP Therapy System, a disposable negative pressure wound therapy (NPWT) line of products from Spiracur, a privately-held medical device company based in Sunnyvale, California.
SNaP® Therapy System is designed to treat a range of complex and hard-to-heal wounds with portable, non-powered negative pressure technology, primarily in the post-acute setting.
The acquisition will allow Acelity’s industry-leading sales and service channels to support the expansion of the SNaP® Therapy System to patients and their care teams around the world who need access to NPWT devices. Terms of the deal were not disclosed.
The acquisition of the SNaP® business accelerates Acelity’s plans for disposable NPWT and increases access to the post-acute market by strengthening the company’s portfolio of offerings for customers in need of comprehensive wound care solutions.
This transaction amplifies the largest range of disposable negative pressure solutions while expanding patient access to these devices through Acelity’s more than 1,800 sales professionals across North America and other developed markets.
The broadened Acelity portfolio has the potential to significantly alter advanced wound care outside the U.S. as portable, disposable NPWT solutions offer a more economical approach to treating chronic wounds in those geographies.
"As an organization, we continually seek out opportunities to fulfill our vision of restoring people’s lives through advancements in wound care technology," said Joe Woody, president and chief executive officer of Acelity.
SNaP® technology offers simple, off the shelf, easy-to-use products and may improve the patient experience due to its size, weight and ability to be discreet, helping mobile patients to return to their normal lives.